Preclinical studies have suggested that patients with high tumor mutational load, high levels of tumor‐infiltrating T cells, and high expression of PD‐L1 would benefit more from anti‐PD‐1/PD‐L1 inhibitors.21 This evidence concerns the gene PDCD1 and neoplasm.